Global Anti-Thyroid Drugs Market Outlook 2024, Forecast To 2033
8 Jan, 2024
The anti-thyroid drugs market has grown steadily, reaching $2.4 billion in 2023 and projected to be $2.46 billion in 2024, reflecting a 2.5% CAGR. The prevalence of thyroid disorders, advancements in drug development, and healthcare infrastructure contributed to historic period growth. Forecasts indicate steady growth, reaching $2.75 billion in 2028, with a 2.8% CAGR. Drivers include patient awareness, healthcare expenditure, demographics, and global economic conditions. Trends encompass thyroid surgery alternatives, patient-centric care, and telemedicine.
Global Anti-Thyroid Drugs Market Key Driver
Graves' disease, a leading cause of hyperthyroidism, is on the rise, driving the demand for anti-thyroid drugs. Graves' disease is more common in individuals aged 30 to 60, and women are 5–10 times more likely to be affected. Genetic predisposition and environmental factors contribute to its prevalence. As the number of Graves' disease cases increases, the overall demand for anti-thyroid drugs is expected to grow, addressing the needs of those with hyperthyroidism.
Get A Free Sample Of The Global Anti-Thyroid Drugs Market ReportGlobal Anti-Thyroid Drugs Market Segments
The anti-thyroid drugs market covered in this report is segmented –
1) By Drug Type: Thionamides (Inhibition of hormone synthesis), Iodides (Inhibition of hormone release)
2) By Route of Administration: Oral, Intravenous, Other Route of Adminitration
3) By Distribution Channel: Wholesaler/Distributors, Retail Chain, Online Distribution, Other Distribution Channels
By Geography: The regions covered in the anti-thyroid drugs market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions
North America was the largest region in the anti-thyroid drugs market in 2023. The Middle East is expected to be the fastest-growing region in the anti-thyroid drugs market during the forecast period. The regions covered in the anti-thyroid drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Anti-Thyroid Drugs Industry Players
Mylan N.V., Abbott Laboratories, GlaxoSmithKline plc, Merck & Co., AbbVie Inc., Pfizer Inc., Allergan plc, RLC LABS Inc., Amgen Inc., Lannett Company Inc., Sanofi S.A., Novartis AG, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Aspen Pharmacare Holdings Limited, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, Daiichi Sankyo Company Limited, Roche Holding AG, Bayer AG, Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Cipla Inc., Lupin Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Ltd., Alkem Laboratories Ltd., Akorn Inc.
Get The Full Global Anti-Thyroid Drugs Market Report
Anti-Thyroid Drugs Market Overview
Anti-thyroid drugs refer to agents that function by preventing the manufacture of thyroid hormones or by reducing the action of thyroid hormones. Additionally, they are suggested for use in radioactive iodine uptake tests to assess thyroid function and safeguard the thyroid gland in case of radiation exposure.
Anti-Thyroid Drugs Global Market Report 2023 provides data on the global anti-thyroid drugs market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The anti-thyroid drugs market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.